Search Results for “research” – Page 8 – media

ICR awarded $25m by Cancer Grand Challenges to research solid tumours in children

Globally, cancer is currently the most leading cause of death due to disease among children The Institute of Cancer Research (ICR) has announced it has been selected to receive a Cancer Grand Challenges (CGC) award of up to $25m to research the challenges of solid tumours in children. First launched in 2020 by Cancer Research UK (CRUK) and the National Cancer Institute (NCI), CGC now brings together 1,200 researchers and 16 teams worldwide to take on 13 of “cancer’s toughest challenges”. Currently the leading cause of death due to disease among children globally, most outcomes for some childhood cancers have not improved in more than three decades. The CGC team PROTECT aims to explore new, less invasive and more targeted treatments for children living with cancers. For the next five years, the PROTECT team, involving experts from the ICR and the Hopp Children’s Cancer Center Heidelberg in Germany, will use ...
- Source: drugdu
- 144
- March 14, 2024
AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced today that the latest results from three preclinical studies of the company’s novel drug candidates olverembatinib, MDM2-p53 inhibitor alrizomadlin, FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, and EED inhibitor APG-5918, have been selected for presentations at the 2024 American Association of Cancer Research Annual Meeting (AACR 2024). These abstracts are now available on the AACR’s official website. The AACR annual meeting is one of the world’s largest and longest-standing scientific gatherings in the field of cancer research. Covering some of the most cutting-edge advances in all the areas of oncology research and innovation, the annual event attracts tremendous interest from the global cancer research community. This year’s AACR annual meeting will be held from April 5-10 2024, in San Diego, California, USA. These three preclinical abstracts from Ascentage Pharma include: ...
- Source: drugdu
- 97
- March 10, 2024
US researchers develop algorithm test to identify aggressive ovarian cancers

Researchers from Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed an algorithm to identify high-risk precancerous lesions that lead to ovarian high-grade serous carcinoma (HGSC). Published in Clinical Cancer Research, researchers aimed to develop a tool that could detect and stratify serous tubal intraepithelial carcinomas (STICs) based on key genetic alterations and mutations. STICs are lesions that are presumed to be the main precursors of HGSC, the most common form of ovarian cancer in women. Using a technique called Repetitive Element AneupLoidy Sequencing System (RealSeqS), researchers sequenced 150 DNA samples and analysed the level of aneuploidy, missing or extra DNA chromosomes, in STIC versus HGSC and normal-appearing samples. Results showed that STIC samples had more non-random genetic alterations, including whole and partial deletions of chromosome 17 in the tumour suppressor p53 proteins, while normal-appearing samples had low levels of aneuploidy. The team suggests ...
- Source: drugdu
- 81
- March 9, 2024
Researchers aim to ensure future AI healthcare monitoring systems are free of gender bias

The project will train a newly developed AI system on data collected from participating men and women Researchers from the University of Glasgow’s James Watt School of Engineering are aiming to ensure that artificial intelligence (AI)-based healthcare monitoring systems in the future are free of gender bias, to improve care for both men and women. For 18 months, the project will examine the potential for gender bias in healthcare AI and discover ways to ensure that AI-supported treatment remains equitable. The use of cutting-edge sensors is currently being investigated to track the rhythms of patients’ hearts and lungs without requiring them to wear monitoring devices or be recorded on video cameras. The team aims to address and ensure that its AI component is properly trained and capable of making the correct judgements without bias towards one gender of patients. Supported by £8,200 in funding from the Université Paris Dauphine-PSL’s Women ...
- Source: drugdu
- 73
- March 8, 2024
Researchers use collected stem cells to grow cell models to advance prenatal medicine

CDH affects one in 5,000 babies born in the UK, impacting the foetus’ development of vital organs Researchers from University College London (UCL) and Great Ormond Street Hospital (GOSH) have developed a new approach to observing human development in late pregnancy to potentially monitor and treat congenital conditions before birth. Published in Nature Medicine, the study used collected stem cells from late pregnancy to create and grow cell models, known as organoids, to retain babies’ biological information. The study of stem cell organoids aims to facilitate the monitoring of foetal development in late pregnancy, model disease progression and test new treatments for diseases including congenital diaphragmatic hernia (CDH). Affecting one in 5,000 babies born in the UK, CDH occurs when there is a hole in the diaphragm, which can lead to the foetus’ bowel, stomach or liver being moved into the chest cavity during pregnancy. Researchers extracted and characterised live ...
- Source: drugdu
- 105
- March 8, 2024
Researchers develop brain-age prediction tool for diagnosis of neurological diseases

The non-invasive tool can also improve patient stratification and monitor disease progression Researchers from King’s College London (KCL) have developed a deep learning framework for a non-invasive brain-age prediction tool for the early diagnosis of neurological diseases. The study built and made available a set of models for clinical use after training multiple brain models from a variety of magnetic resonance image (MRI) types. Neurological disorders, such as Alzheimer’s disease, strokes, multiple sclerosis and Parkinson’s disease, are conditions that affect the brain as well as the nerves found throughout the human body and spinal cord. By comparing patients’ brain ages against their chronological ages, numerous neurological and psychiatric conditions can be identified, helping to predict future health outcomes for patients. Researchers collected over 81,000 patients’ head MRI examinations from Guy’s and St Thomas’ NHS Foundation Trust and King’s College Hospital NHS Foundation Trust between 2008 and 2019. After pre-training models, ...
- Source: drugdu
- 87
- March 7, 2024
Researchers reveal two different subtypes of prostate cancer using AI

In the UK alone, the aggressive form of cancer affects around 52,000 men every year Researchers from the University of Oxford and the University of Manchester have revealed that prostate cancer is not just a single disease and is made up of two different evotypes – subtypes of the disease. Published in Cell Genomics, the study, funded by Cancer Research UK and Prostate Cancer Research, used artificial intelligence (AI) to reveal a new form of aggressive prostate cancer. Currently the most common cancer affecting men in the UK, prostate cancer is responsible for around 52,000 cases every year. As part of the Pan Prostate Cancer Group; an international consortium set up by the Institute of Cancer Research (ICR) and the University of East Anglia (UEA), researchers applied AI to analyse the genetic data of 159 prostate cancer patient samples across nine countries. Using whole genome sequencing to study changes in ...
- Source: drugdu
- 130
- March 6, 2024
Researchers reveal COVID-19 could have small impacts on cognition and memory

Different factors, such as illness duration and virus variant, impacted patients cognitive abilities Imperial College London (ICL) researchers have revealed that people who have recovered from COVID-19 could have small but long-lasting impacts on the performance of cognitive and memory tasks. Published in the New England Journal of Medicine, the REACT Long COVID study enrolled over 140,000 participants, including long COVID patients, who undertook at least one cognitive task. COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. For some patients, the condition can lead to long COVID, where symptoms can last up to 12 weeks. Using an innovative online cognitive assessment via the Cognitron platform, researchers detected subtle changes in different areas of brain function, including memory, reasoning, executive function, attention and impulsivity. The study revealed small deficits that were still detectable after a year or more following infection, including in people who had a short duration of ...
- Source: drugdu
- 93
- March 5, 2024
UK and Netherlands researchers call for funding to investigate cancer treatments

The white paper outlines three strategic recommendations to support further research Researchers from King’s College London and Erasmus MC in the Netherlands have called for further funding support in a recently published white paper to investigate the use of radioactive cancer-targeted drugs to improve cancer treatments. The white paper, Unlocking the Full Potential of Cancer Treatments Using Targeted Radionuclide Therapy through Netherlands-UK Partnerships, outlined three strategic recommendations to achieve this. Most radioactive drugs are used to specifically deliver a radiation dose to cancer cells to produce a therapeutic effect. They are used to treat the disease areas identified on medical scans but can also specifically target the microscopic tumour deposits, which are involved in the progression of the disease. More specifically, targeted radionuclide therapy, a type of radiation therapy, is effective to treat prostate cancer and some other types of cancer where radionuclide, a radioactive chemical, is linked to cell-targeting ...
- Source: drugdu
- 156
- February 29, 2024
Researchers develop terahertz biosensor to detect skin cancer for early diagnosis

Results from the study could also be used for other forms of cancer and diseases Researchers from the University of Glasgow and Queen Mary University of London have developed a new biosensor using terahertz (THz) waves that can detect skin cancer with strong sensitivity. Published in the IEEE Transactions on Biomedical Engineering, the study results could pave the way for easier and earlier diagnoses of skin cancer and potentially other cancers and diseases. Affecting one in four men and one in five women at least once in their lifetime in the UK, skin cancer is an abnormal growth of skin cells that involves three major types: basal cell carcinoma (BCC), squamous cell carcinoma and melanoma. Most skin cancer is often detected using traditional methods that involve expensive, time-consuming CT and PET scans, and invasive higher-frequency technology. After exploring the potential of THz metasurfaces, researchers designed the biosensor to detect subtle ...
- Source: drugdu
- 155
- February 28, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.